CRANBURY, N.J.-- (BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood ...
—Preliminary Data from First Patient Demonstrates Initial Safety and Tolerability of RP-L301, Near Doubling of Hemoglobin to Normal Range and Additional Normalization of Hemolysis Markers— —Rocket’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results